Publications

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 400, 359 - 368

Allocated but not treated: the silent 16%

Horby P. et al, (2022), LANCET, 399, 1776 - 1776

Allocated but not treated: the silent 16% - Authors' reply.

Horby P. et al, (2022), Lancet (London, England), 399, 1775 - 1776

Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices).

Fraser AG. et al, (2022), European heart journal. Quality of care & clinical outcomes, 8, 249 - 258

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting: Rationale and Design of the DANFLU-1 Trial

LANDRAY M., (2022), Pilot and Feasibility Studies

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), European heart journal, 43, 1416 - 1424

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

RECOVERY Collaborative Group None. et al, (2022)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet (London, England), 399, 143 - 151

Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments.

Cake C. et al, (2022), Trials, 23

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2022)

Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2022)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.

Harper C. et al, (2021), JAMA network open, 4

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2021), Lancet Respiratory Medicine, 9, 1419 - 1426

Impact of adverse events on quality of life and hospital costs in secondary cardiovascular disease prevention

Lui NMJ. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3159 - 3159

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2021), JAMA

Making trials part of good clinical care: lessons from the RECOVERY trial.

Pessoa-Amorim G. et al, (2021), Future healthcare journal, 8, e243 - e250

Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

Horby P. et al, (2021), Lancet (London, England), 398

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2021)

Cookies on this website

Publications